Regenerative Medicine: Injectable Cell-Based Therapeutics and Approved Products

Golchin, Ali; Shams, Forough; Kangari, Parisa; Azari, Amir A.; Hosseinzadeh, Simzar

doi:10.1007/5584_2019_412

Cited by 19 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, leukocytes can actively move through these chemokine gradients onto these nanoparticles towards tumor cells and consequently stimulate these cells as ultimate targets. Therapeutic delivery systems are one of the main challenges in therapeutic approaches [ 12 , 33 ]. The delivery of immune-stimulatory drugs to antitumor immune cells brings about cancerous cells rather than delivering cytotoxic drugs, which results in almost no risk of recurrence.…”

Section: Nanotechnology and Cancer Immunotherapymentioning

confidence: 99%

Nanotechnology-based products for cancer immunotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

Section: Nanotechnology and Cancer Immunotherapymentioning

confidence: 99%

Nanotechnology-based products for cancer immunotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

“…Over the past two decades, significant advances have been made in the field of regenerative medicine, which focuses on developing methods to restore, regrow or replace damaged or dysfunctional cells, tissues and organs [ 1 ]. In 2009, Chondroselect (TiGenix N.V.) was the first regenerative cellular therapy that entered the European market, using autologous ex vivo expanded chondrocytes.…”

Section: Introductionmentioning

confidence: 99%

Are Cell-Based Therapies Safe and Effective in the Treatment of Neurodegenerative Diseases? A Systematic Review with Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Over the past two decades, significant advances have been made in the field of regenerative medicine. However, despite being of the utmost clinical urgency, there remains a paucity of therapeutic strategies for conditions with substantial neurodegeneration such as (progressive) multiple sclerosis (MS), spinal cord injury (SCI), Parkinson’s disease (PD) and Alzheimer’s disease (AD). Different cell types, such as mesenchymal stromal cells (MSC), neuronal stem cells (NSC), olfactory ensheathing cells (OEC), neurons and a variety of others, already demonstrated safety and regenerative or neuroprotective properties in the central nervous system during the preclinical phase. As a result of these promising findings, in recent years, these necessary types of cell therapies have been intensively tested in clinical trials to establish whether these results could be confirmed in patients. However, extensive research is still needed regarding elucidating the exact mechanism of action, possible immune rejection, functionality and survival of the administered cells, dose, frequency and administration route. To summarize the current state of knowledge, we conducted a systematic review with meta-analysis. A total of 27,043 records were reviewed by two independent assessors and 71 records were included in the final quantitative analysis. These results show that the overall frequency of serious adverse events was low: 0.03 (95% CI: 0.01–0.08). In addition, several trials in MS and SCI reported efficacy data, demonstrating some promising results on clinical outcomes. All randomized controlled studies were at a low risk of bias due to appropriate blinding of the treatment, including assessors and patients. In conclusion, cell-based therapies in neurodegenerative disease are safe and feasible while showing promising clinical improvements. Nevertheless, given their high heterogeneity, the results require a cautious approach. We advocate for the harmonization of study protocols of trials investigating cell-based therapies in neurodegenerative diseases, adverse event reporting and investigation of clinical outcomes.

show abstract

“…Cell-based therapies have been adopted for diseases involving a variety of organs and cell types [19][20][21][22][23][24][25][26][27][28][29][30][31], and in combination with therapeutic gene correction of long-lived lung epithelial progenitors, may represent a plausible approach for monogenic lung diseases such as cystic fibrosis [32][33][34]. However, realization of stem cell-based therapeutic approaches for lung regenerative medicine will require development and validation of reproducible protocols allowing standardization and scalability, as has been demonstrated in other tissues [35][36][37][38].…”

Section: Introductionmentioning

confidence: 99%

Cryobanking of human distal lung epithelial cells for preservation of their phenotypic and functional characteristics

Konda

Mulay

Yao

et al. 2021

Preprint

View full text Add to dashboard Cite

The epithelium lining airspaces of the human lung is maintained by regional stem cells including basal cells of pseudostratified airways and alveolar type 2 pneumocytes (AT2) of the alveolar gas-exchange region. Despite effective methods for long-term preservation of airway basal cells, methods for efficient preservation of functional epithelial cell types of the distal gas-exchange region are lacking. Here we detail a method for cryobanking of epithelial cells from either mouse or human lung tissue for preservation of their phenotypic and functional characteristics. Flow cytometric profiling, epithelial organoid-forming efficiency, and single cell transcriptomic analysis, were used to compare cells recovered from cryopreserved tissue with those of freshly dissociated tissue. Alveolar type 2 cells within single cell suspensions of enzymatically digested cryobanked distal lung tissue retained expression of the pan-epithelial marker CD326 and the AT2 cell surface antigen recognized by monoclonal antibody HTII-280, allowing antibody-mediated enrichment and downstream analysis. Isolated AT2 cells from cryobanked tissue were comparable with those of freshly dissociated tissue both in their single cell transcriptome and their capacity for in vitro organoid formation in 3D cultures. We conclude that the cryobanking method described herein allows long-term preservation of distal human lung tissue for downstream analysis of lung cell function and molecular phenotype, and is ideally suited for creation of an easily accessible tissue resource for the research community.

show abstract

Regenerative Medicine: Injectable Cell-Based Therapeutics and Approved Products

Cited by 19 publications

References 40 publications

Nanotechnology-based products for cancer immunotherapy

Nanotechnology-based products for cancer immunotherapy

Are Cell-Based Therapies Safe and Effective in the Treatment of Neurodegenerative Diseases? A Systematic Review with Meta-Analysis

Cryobanking of human distal lung epithelial cells for preservation of their phenotypic and functional characteristics

Contact Info

Product

Resources

About